J Clin Invest. 2020;130(1):491-506. https://doi.org/10.1172/JCI129382. b-Thalassemia is a genetic anemia caused by partial or complete loss of b-globin synthesis, leading to ineffective erythropoiesis and RBCs with a short life span. Currently, there is no efficacious oral medication modifying anemia for patients with b-thalassemia. The inappropriately low levels of the iron regulatory hormone hepcidin enable excessive iron absorption by ferroportin, the unique cellular iron exporter in mammals, leading to organ iron overload and associated morbidities. Correction of unbalanced iron absorption and recycling by induction of hepcidin synthesis or treatment with hepcidin mimetics ameliorates b-thalassemia. However, hepcidin modulation or replacement strategies currently in clinical development all require parenteral drug administration. We identified oral ferroportin inhibitors by screening a library of small molecular weight compounds for modulators of ferroportin internalization. Restricting iron availability by VIT-2763, the first clinical stage oral ferroportin inhibitor, ameliorated anemia and the dysregulated iron homeostasis in the Hbb th3/+ mouse model of b-thalassemia intermedia. VIT-2763 not only improved erythropoiesis but also corrected the proportions of myeloid precursors in spleens of Hbb th3/+ mice. VIT-2763 is currently being developed as an oral drug targeting ferroportin for the treatment of b-thalassemia.
Introduction β-Thalassemia is an inherited anemia caused by mutations in the β-globin gene of hemoglobin (Hb) resulting in abnormal RBCs with decreased life span (1, 2). In healthy subjects, Hb is composed of α-and β-globin chains, which, together with the iron-containing heme groups, form functional α 2 β 2 heterotetramers within RBCs to efficiently deliver oxygen to tissues. The main pathophysiological mechanism in β-thalassemia results from the decreased synthesis of β-globin chains, causing accumulation of unpaired α-globin aggregates on the membranes of RBCs. Precipitated α-globin aggregates contain heme and iron, which generate ROS leading to a shortened life span of RBCs, anemia, and tissue hypoxia (3, 4) . As a compensatory response to the reduced life span of RBCs in β-thalassemia patients, erythropoiesis is greatly stimulated, leading to increased proliferation and decreased differentiation of erythroid precursors (ineffective erythropoiesis) in BM and extramedullary sites, such as spleen and liver (5) . The ineffective erythropoiesis in β-thalassemia substantially contributes to the anemia and causes iron overabsorption to support the increased iron demand for Hb synthesis, leading to organ iron overload. Liver, spleen, heart, and pancreas are the tissues commonly affected by iron overload, and without therapeutic intervention, iron overload may lead to organ damage, such as liver cirrhosis, heart failure, and diabetes.
The homeostatic regulation of iron absorption and distribution is controlled by hepcidin, a 25 aa peptide produced mainly in the liver (6) . Hepcidin inhibits ferroportin (SLC40A1), the only known cellular iron exporter (7, 8) . Ferroportin on the basolateral membrane of intestinal enterocytes transfers dietary iron into the plasma; on spleen and liver macrophages, it exports recycled iron from the Hb of senescent RBCs, and ferroportin on hepatocytes exports iron from liver stores (9) . Recently, Zhang et al. have demonstrated that ferroportin is highly abundant on mature RBCs and has an essential role in maintaining systemic iron homeostasis and protecting RBCs from oxidative stress (10, 11) . Hepcidin binds to and triggers ferroportin internalization and degradation, which causes a rapid drop in blood iron levels (12) . In addition, hepcidin inhibits iron export, not only by causing ferroportin endocytosis, but also by directly occluding the transporter (13) . Hepcidin transcription is downregulated by erythropoiesis, iron deficiency, and hypoxia, whereas inflammation and high systemic iron levels lead to hepcidin upregulation (6, 14) .
The ineffective erythropoiesis in β-thalassemia causes iron overabsorption due to feedback compensatory response to hypoxia, which suppresses hepcidin (15) . Since the abnormally high iron levels that result from the suppression of hepcidin further stimulate erythropoiesis, anemia and iron overload are worsened in a vicious circle. HIF2α plays a major role in linking erythropoiesis and iron absorption, as HIF2α stimulates both erythropoietin (EPO) production and upregulates expression of the divalent metal transporter 1 (DMT1), duodenal cytochrome B (DCytB), and ferroportin (14, 16) . EPO β-Thalassemia is a genetic anemia caused by partial or complete loss of β-globin synthesis, leading to ineffective erythropoiesis and RBCs with a short life span. Currently, there is no efficacious oral medication modifying anemia for patients with β-thalassemia. The inappropriately low levels of the iron regulatory hormone hepcidin enable excessive iron absorption by ferroportin, the unique cellular iron exporter in mammals, leading to organ iron overload and associated morbidities. Correction of unbalanced iron absorption and recycling by induction of hepcidin synthesis or treatment with hepcidin mimetics ameliorates β-thalassemia. However, hepcidin modulation or replacement strategies currently in clinical development all require parenteral drug administration. We identified oral ferroportin inhibitors by screening a library of small molecular weight compounds for modulators of ferroportin internalization. Restricting iron availability by VIT-2763, the first clinical stage oral ferroportin inhibitor, ameliorated anemia and the dysregulated iron homeostasis in the Hbb th3/+ mouse model of β-thalassemia intermedia. VIT-2763 not only improved erythropoiesis but also corrected the proportions of myeloid precursors in spleens of Hbb th3/+ mice. VIT-2763 is currently being developed as an oral drug targeting ferroportin for the treatment of β-thalassemia.
Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia their ability to inhibit binding and internalization of fluorescently labeled hepcidin (6-carboxytetramethylrhodamine hepcidin [TMR-hepcidin]) in the mouse macrophage cell line J774, which expresses endogenous ferroportin. In addition, a fluorescence polarization binding assay was used to more directly demonstrate inhibition of TMR-hepcidin binding to purified recombinant human ferroportin. Compounds that showed inhibition of TMR-hepcidin binding to ferroportin were further profiled with functional assays, including ferroportin internalization and iron efflux assays ( Figure  1A) . Lead structures were optimized for potency, drug metabolism, and pharmacokinetics (PKs) parameters by medicinal chemistry, and selected compounds were tested for acute efficacy in inducing hypoferremia in C57BL/6 mice. Finally, a small number of preclinical candidates were tested for efficacy in the Hbb th3/+ mouse model of β-thalassemia intermedia ( Figure 1A) .
The clinical compound, VIT-2763 ( Figure 1B) is a small organic heterocyclic molecule that has been evaluated in biological assays as a salt of the organic base (MW 408.43 g/mol).
VIT-2763 inhibits hepcidin binding to ferroportin and blocks iron efflux. Potencies of ferroportin binding were compared between VIT-2763 and hepcidin in a competition assay using the macrophage cell line J774, in which expression of ferroportin can be triggered with iron. The small molecule VIT-2763 competed for binding and internalization of fluorescently labeled TMR-hepcidin with IC 50 of 9 ± 5 nM, mean ± SD, which was within the range of the potency of unlabeled synthetic hepcidin (IC 50 = 13 ± 4 nM, mean ± SD) in the same assay ( Figure 2 , A and B).
To investigate the potency of VIT-2763 in a cell-free assay without interference of ferroportin internalization, we used purified human ferroportin expressed in yeast in a fluorescence polarization assay. The binding of TMR-hepcidin to ferroportin leads to increased fluorescence polarization of the TMR-hepcidin ligand. Addition of VIT-2763 dose dependently reduced the fluorescence polarization signal, indicating that VIT-2763 displaces TMR-hepcidin from ferroportin ( Figure 2C , IC 50 of 24 ± 13 nM, mean ± SD). The binding of TMR-hepcidin to ferroportin was dose dependently inhibited by unlabeled full-length human hepcidin (hepcidin-25), although with a lower potency compared with VIT-2763 ( Figure 2C , IC 50 of 533 ± 250 nM, mean ± SD). A truncated inactive version of hepcidin (hepcidin-20), lacking the first 5 N-terminal amino acids involved in ferroportin binding (23) , failed to decrease the fluorescence polarization signal (Sup-triggers the proliferation of erythroblasts and induces the production of the erythroid factor erythroferrone (ERFE), which in turn suppresses hepcidin (17) .
Therefore, correction of unbalanced iron absorption by induction of hepcidin synthesis or supplementation of hepcidin mimetics is an attractive therapeutic approach for normalizing the dysregulated iron metabolism in β-thalassemia. Experimental drugs, such as shortened hepcidin-derived peptides containing unnatural amino acids (minihepcidins) or oligonucleotides that increase endogenous hepcidin synthesis by inhibition of Tmprss6, have been shown to correct anemia and decrease iron overload in the Hbb th3/+ mouse model of β-thalassemia intermedia (18) (19) (20) . In addition, synthetic human hepcidin (LJPC-401) as well as a hepcidin peptidomimetic (PTG-300) and an anti-sense oligonucleotide targeting Tmprss6 (IONIS-TMPRSS6-L RX ) have been tested in phase I clinical studies. Hepcidin modulation or replacement strategies currently in clinical development all require parenteral administration. Orally bioavailable minihepcidins have been shown to lower serum iron in WT mice (21) . Nevertheless, presently no clinical data for an oral drug targeting ferroportin have been published. Oral drug administration offers advantages over parenteral, such as the ease of administration by patients, in par ticular children, high degree of flexibility on dosages and formu lation, cost effectiveness, fewer sterility constraints, and no risk of injection site reactions and infection. Parenteral administration of drugs usually requires medical attendance, which further increases treatment costs and may negatively affect patient compliance.
The scope of the present publication is to describe the profile and mode of action of the compound VIT-2763, an oral small molecule inhibitor of ferroportin. Based on the promising preclinical efficacy and tolerability profile, VIT-2763 has entered clinical development (22) . Since no oral ferroportin inhibitors or hepcidinmimetic drugs are available for the treatment of iron overload and ineffective erythropoiesis, VIT-2763 is considered the first oral drug candidate to reach the clinical development stage.
Results
Ferroportin inhibitors were discovered by screening a small molecule library. Ferroportin inhibitors were identified by screening a library of small molecular weight compounds (250,000 compounds) for modulators of ferroportin internalization using Madin-Darby canine kidney (MDCK) cells expressing fluorescently tagged human ferroportin. Confirmed hit compounds were then tested for To investigate whether the observed inhibition of cellular iron export by VIT-2763 is dependent on ferroportin, we used HEK293 cells expressing a doxycycline-inducible human ferroportin fused to GFP. In addition, this cell line contains the promoter and adjacent 5′ UTR with the iron regulatory element (IRE) of the human ferritin H gene fused to a β-lactamase (BLA) reporter gene that is activated by rising intracellular iron levels. Treatment of these cells with doxycycline and VIT-2763 induced BLA reporter gene activity with an average EC 50 of 140 ± 50 nM, mean ± SD, as a consequence of increasing intracellular iron concentrations caused by blocked iron export ( Figure 2E ). However, the potency of hepcidin in this iron retention assay was higher with an EC 50 of 39 ± 20 nM, mean ± SD, ( Figure 2F ). The effects of VIT-2763 and hepcidin were dependent of ferroportin, as shown by lack of activity when ferroportin was not induced by doxycycline addition.
In conclusion, the small molecule VIT-2763 inhibited binding of hepcidin to ferroportin, thereby preventing the internalization of fluorescently labeled hepcidin. Importantly, VIT-2763 inhibited the cellular iron efflux in a ferroportin-dependent manner and with potency comparable to hepcidin, the physiological peptide ligand of ferroportin.
VIT-2763 triggers ubiquitination and subsequent internalization and degradation of ferroportin. The generally accepted mechanism by which hepcidin regulates cellular iron export is that hepcidin binds to ferroportin, triggering its ubiquitination, internalization, and degradation, thereby blocking the iron export activity of ferroportin plemental Figure 1 ; supplemental material available online with this article; https://doi.org/10.1172/JCI129382DS1). Furthermore, the potency of structurally related ferroportin inhibitors measured in J774 TMR-hepcidin internalization assay correlated significantly with the potency of the same compounds measured in the fluorescence polarization assay (Supplemental Figure 2 ). Based on these data, we concluded that the purified ferroportin shows ligand-binding properties similar to those of the native ferroportin expressed on the cell membrane.
The results with both TMR-hepcidin assays showed that VIT-2763 competes with hepcidin for ferroportin binding and internalization; however, these assays do not provide functional information for the effect of VIT-2763 on iron export activity of ferroportin. To address the effect of VIT-2763 on ferroportin function, the human breast cancer cell line T47D expressing endogenous ferroportin was incubated with iron sulfate labeled with the stable isotope 58 Fe for 20 hours and cells were treated with either VIT-2763 or hepcidin alone or both compounds added simultaneously. Hepcidin blocked the cellular iron efflux dose dependently, as measured by quantification of 58 Fe in the cell supernatant, with an average EC 50 of 123 ± 46 nM, mean ± SD. Importantly, VIT-2763 inhibited the iron efflux with a slightly higher potency than hepcidin (EC 50 of 68 ± 21 nM, mean ± SD). No additive effect was observed by preincubation (not shown) of either VIT-2763 or hepcidin or by coincubation of both at equimolar concentrations ( Figure 2D ). 3A). Hepcidin treatment for 18 hours induced dose-dependent internalization of ferroportin in MDCK cells, as detected by disappearance of surface TMR signal by fluorescence microscopy (Figure 3B ). The potency of hepcidin in the MDCK assay was higher than the potency of VIT-2763 (long-term average: hepcidin EC 50 = 1.5 ± 0.9 nM; VIT-2763 EC 50 = 14.4 ± 8.1 nM, mean ± SD). Interestingly, the maximal response of VIT-2763 (curve span) was in average 21% lower than the response of hepcidin, suggesting that the ferroportin internalization triggered by VIT-2763 was not complete ( Figure 3 , A and B). The kinetic effects of hepcidin and VIT-2763 on ferroportin expression were compared using concentrations resulting in a maximal effect for each molecule. Hepcidin (1 μM) triggered ferroportin internalization and formation of intracellular vesicles starting at 20 minutes, increasing at 1 hour, and resulting in a complete ferroportin internalization from the plasma membrane at 3 hours and degradation by 3 to 6 hours ( Figure 3 , A-C). Remarkably, the small molecule indirectly by targeting ferroportin for degradation (6, 24, 25) . More recently, structural and mutational analyses of a bacterial ferroportin homologue (26) and mammalian ferroportin (13) suggested that hepcidin may inhibit ferroportin directly by occlusion in the absence of ferroportin endocytosis and degradation. We hypothesized that VIT-2763, despite being structurally unrelated, mimics the function of the hepcidin peptide. The TMR-hepcidin assay in J774 cells described above does not distinguish binding to ferroportin from internalization of ferroportin. To study the mechanism of action of VIT-2763 we employed 2 approaches:(a) ferroportin internalization assay with MDCK cells expressing human ferroportin with a fluorescent HaloTag; (b) immunoprecipitation studies to assess ferroportin ubiquitination in J774 cells expressing endogenous ferroportin.
MDCK cells constitutively expressing human ferroportin fused to a HaloTag that allows labeling with the fluorescent TMR-HaloTag ligand were treated with either VIT-2763 or hepcidin for 20 minutes, 1 hour, 3 hours, 6 hours, and 18 hours (Figure Figure 4A ). Orally dosed VIT-2763 showed a moderate half-life of 2.0 ± 0.8 hours (mean ± SD) and good bioavailability of 48.3% ± 9.9% (mean ± SD) in rats. Injection of synthetic hepcidin in mice has been shown to decrease plasma iron levels, consistent with a blockade of iron absorption and iron export from tissue stores and from macrophages involved in iron recycling (12) . Plasma iron was measured as a marker for PD activity of VIT-2763 in vivo. Plasma iron in rats dosed orally with VIT-2763 decreased over time, reaching minimal levels 4 hours after oral dosing and recovering within 8 to 24 hours. Interestingly, plasma iron levels at 24 hours were higher than at baseline (5 minutes after dose), most likely due to a regulatory feedback response to hypoferremia ( Figure 4A ). To compare the efficacy of hepcidin and VIT-2763 in vivo, an acute model of hypoferremia in C57BL/6 mice was used. Injection of synthetic human hepcidin i.p. (5 mg/kg) into mice resulted in a significant reduction of serum iron levels at 1 hour, 3 hours, and 6 hours (32%, 59%, and 34% lower than the vehicle, respectively, Figure 4B ). VIT-2763 dosed orally at 60 mg/kg rapidly decreased serum iron at 1 hour and 3 hours to levels comparable to those seen with hepcidin (40% and 58% lower than the vehicle), demonstrating similar effects of VIT-2763 and hepcidin in C57BL/6 mice from 1 hour to 3 hours after dosing ( Figure 4 , B and C). Serum iron levels in mice treated with VIT-2763 for 6 hours did not change significantly compared with those in the vehicle group. Both, hepcidin and VIT-2763 had no effect on serum iron levels at 16 hours after dose was given.
VIT-2763 decreased iron overload in the Hbb th3/+ mouse model of β-thalassemia intermedia. Parenteral administration of agents that induce the synthesis of endogenous hepcidin or modified hepcidin peptides has been shown to correct ineffective erythropoiesis and to ameliorate iron overload in the Hbb th3/+ model of β-thalassemia intermedia (18) (19) (20) . Based on the similar mode of action of VIT-2763 and hepcidin in cell-based and biophysical assays, as well as acute efficacy in WT rodents, we hypothesized that VIT-2763 might improve the pathophysiological parameters in the Hbb th3/+ model of β-thalassemia intermedia and provide a preclinical proof of concept for development of oral ferroportin inhibitor for therapy of β-thalassemia.
VIT-2763 (20 μM) also induced ferroportin internalization, although with slower kinetics and incomplete disappearance of ferroportin from the plasma membrane, even after compound exposure for 18 hours (Figure 3 Figure 2C suggested that VIT-2763 competes with hepcidin for ferroportin binding and internalization.
Immunoprecipitation studies performed using J774 cells expressing endogenous ferroportin showed that both VIT-2763 and hepcidin triggered ubiquitination and degradation of ferroportin. Treatment of J774 cells with hepcidin or VIT-2763 led to a rapid ubiquitination of ferroportin within 10 to 20 minutes and degradation of ferroportin starting at 40 to 120 minutes ( Figure 3D ). However, hepcidin induced almost full disappearance of the ferroportin signal, whereas VIT-2763 treatment for 120 minutes resulted in incomplete ferroportin degradation. In addition, hepcidin induced ferroportin ubiquitination products with higher molecular weight (~100 kDa) compared with VIT-2763 (~70 kDa), suggesting a different degree of ubiquitination (4-5 vs. 1-2 ubiquitin molecules per ferroportin, respectively).
The immunoprecipitation experiments in J774 cells suggested that both VIT-2763 and hepcidin utilize similar pathways of ferroportin internalization and degradation. Nevertheless, slight differences in efficacy and kinetics were demonstrated, which is in agreement with the slower kinetics and less complete degradation of ferroportin in MDCK cells expressing fluorescently labeled human ferroportin.
VIT-2763 reduced serum iron levels in rodents. To investigate the in vivo bioavailability and biological activity of VIT-2763, we determined its PK and pharmacodynamic (PD) properties Hbb th3/+ mice absorb excessive amounts of iron as a consequence of inadequately low hepcidin levels relative to the high iron content in liver, spleen, and kidney and increased ferroportin expression in the duodenum (27) . To investigate the efficacy of VIT-2763 in the Hbb th3/+ model, mice were fed a diet with a low amount of iron (<10 mg/kg) and dosed orally with either 30 or 100 mg/kg VIT-2763 or vehicle twice daily (bid) for 36 days. In between compound doses, mice had access to drinking water containing the stable iron isotope 58 Fe, which allowed differentiating iron absorbed during and before the study. Treatment of Hbb th3/+ mice with 30 or 100 mg/kg VIT-2763 significantly decreased serum iron levels, by 77% and 84%, relative to the vehicle Hbb th3/+ group, respectively ( Figure 5A ), demonstrating the acute effect of the compound on systemic iron. As expected, by blocking ferroportin on liver macrophages and hepatocytes, VIT-2763 did not change the total liver iron. However, VIT-2763 very efficiently prevented additional liver iron loading during the study, as shown by a dose-dependent reduction of 58 Fe concentration in liver ( Figure 5 , B and C).
The ineffective erythropoiesis in Hbb th3/+ mice causes excessive proliferation of erythroid precursors and expansion of the red pulp in the spleen, leading to splenomegaly. Treatment of Hbb th3/+ mice with VIT-2763 resulted in a significant reduction of the relative spleen weight, by 52% and 65% of the Hbb th3/+ vehicle control for 30 and 100 mg/kg VIT-2763, respectively ( Figure 5D ). Furthermore, Hbb th3/+ mice receiving VIT-2763 showed improved distribution of spleen red and white pulp compartments and had a less diffuse iron-staining pattern compared with Hbb th3/+ mice treated with vehicle ( Figure 5F ). These results highlight the potential of the oral ferroportin inhibitor to attenuate excessive extramedullar erythropoiesis in spleen. The concentration of spleen iron increased dose dependently (not shown), consistent with the decrease in the spleen weight and retention of iron in spleen macrophages; however, the total spleen iron content remained unchanged in the group treated with 30 mg/kg and decreased significantly in mice treated with the 100 mg/kg compound ( Figure 5E ).
VIT-2763 ameliorated anemia and improved ineffective erythropoiesis in Hbb th3/+ mice. Notably, ferroportin inhibition with the oral drug VIT-2763 not only decreased plasma and organ iron levels, but also improved the hematological parameters in Hbb th3/+ mice. VIT-2763 significantly increased Hb levels (as of day 8 of treatment; Figure 6A ), RBC counts ( Figure 6B ), mean corpuscular Hb concentration (MCHC) ( Figure 6C ), and significantly lowered reticulocyte counts ( Figure 6D ), mean corpuscular Hb (MCH) ( Figure 6E ), mean corpuscular volume (MCV) ( Figure 6F ), and RBC distribution width (RDW) ( Figure 6G ) in Hbb th3/+ mice, as compared with the Hbb th3/+ vehicle group. Therefore, ferroportin inhibition by VIT-2763 significantly ( Figure 6 ) ameliorated anemia and corrected pathologically altered RBCs and reticulocyte counts, indicating improved erythropoiesis in Hbb th3/+ mice. Remarkably, dietary iron restriction of Hbb th3/+ mice for the dura- tion of the study failed to lower serum iron and improve anemia (data not shown), demonstrating that iron restriction by pharmacological inhibition of ferroportin is necessary for a substantial therapeutic effect. The central pathophysiological mechanism in β-thalassemia is ineffective erythropoiesis, which is characterized by increased proliferation and decreased differentiation of erythroid progenitors in hematopoietic organs. As a result of the α/β globin imbalance, RBCs accumulate toxic membrane α-globin aggregates and produce excessive ROS. The effect of VIT-2763 on erythropoiesis was studied by analyzing the percentage of differentiating erythroid precursors in BM and spleen based on Ter119 and CD44 markers. VIT-2763 reduced the percentages of the early erythroid precursors proerythroblasts ( Figure 7 Figure 4 ). The increased proportion of mature erythroid cells and decreased oxidative stress in BM and spleens of Hbb th3/+ mice together with the reduced apoptosis of mature RBCs and RBC precursors in blood suggest that VIT-2763 ameliorated the ineffective erythropoiesis in Hbb th3/+ mice.
VIT-2763 reduced the formation of α-globin aggregates and extended the life span and improved the functional parameters of circulating RBCs in Hbb th3/+ mice. To investigate how VIT-2763 improves anemia and iron overload, Hbb th3/+ mice were treated with the compound for 4 to 7 weeks and a broader range of biomarkers was investigated in several independent studies.
In β-thalassemia intermedia, the imbalanced synthesis of α-and β-globin chains of Hb leads to formation of insoluble α-globin aggregates containing free heme and iron, causing ROS formation and apoptosis of the late-stage erythroid progenitors. Analysis of the membrane-bound globins by triton acetic acid urea (TAU) gel electrophoresis showed a dosedependent decrease in the levels of toxic α-globin aggregates in RBC membrane preparations from Hbb th3/+ mice treated with VIT-2763 for 28 days compared with the Hbb th3/+ vehicle group ( Figure  8A ). The reduction of the membrane α-globin was present as early as day 8 of compound treatment (data not shown) and further decreased in the following 2 weeks, suggesting a rapid improvement of erythropoiesis. The insoluble globin aggregates on RBC membranes contain products of Hb oxidative denaturation, such as metHb, free heme, and iron, which all contribute to ROS generation in RBCs (28) . In agreement with the reduced α-globin aggregates in RBCs, VIT-2763 decreased the percentage of ROSpositive RBCs in Hbb th3/+ mice from 67% to 30% ( Figure 8B ).
Reticulocytes of healthy individuals clear mitochondria by mitophagy during maturation, and terminally differentiated RBCs produce energy by glycolysis (29) . However, it has been shown that mitophagy in β-thalassemia is impaired, resulting in retention of mitochondria in mature RBCs (30, 31) . Flow cytometry analysis of MitoTracker-labeled blood cells showed that essentially all reticulocytes from both WT and Hbb th3/+ mice contained mitochondria (MitoTracker + cells, Figure 9A ). Upon maturation, RBCs from WT mice progressively eliminated their mitochondria, with only 1.5% of terminally differentiated RBCs retaining RBCs for phagocytosis by scavenging macrophages that deliver the damaged RBCs to spleen and liver for degradation (33) . The released heme is catabolized by heme oxygenase 1 (HMOX1), which is upregulated in β-thalassemia due to excessive RBC apoptosis (34) . VIT-2763 treatment significantly reduced the expression of Hmox1 in livers of Hbb th3/+ mice, most likely as a result of the decreased RBC turnover ( Figure 10B ). Indeed, the half-life of RBCs in Hbb th3/+ mice treated with vehicle was 8 days and administration of VIT-2763 extended it to 22 days, which was similar to the half-life of RBCs in WT mice ( Figure 10C ). VIT-2763 ameliorated hypoxia in Hbb th3/+ mice. Hbb th3/+ mice are systemically hypoxic as a result of inappropriate tissue oxygenation by the defective RBCs (14, 18) . Indeed, flow cytometry analysis of RBCs stained with a fluorescent surrogate marker for hypoxia (Enzo Life Sciences) confirmed a higher MFI signal in Hbb th3/+ mice treated with vehicle compared with WT mice ( Figure 11A ). RBCs from Hbb th3/+ mice that received VIT-2763 for 4 weeks showed reduced MFI levels of the fluorogenic hypoxia marker, suggesting improved oxygenation of RBCs ( Figure 11A ). Hypoxia is in the center of the vicious circle driving iron overabsorption and ineffective erythropoiesis in β-thalassemia by upregulating genes involved in iron uptake and erythropoiesis, such as DMT1, DcytB, ferroportin, and EPO. The effect of VIT-2763 on the hypoxia-sensitive marker in RBCs is most likely indirect and mediated by the improved erythropoiesis and increased Hb resulting in a better tissue oxygenation. Consistent with the improvement of tissue oxygenation, Hbb th3/+ mice treated with VIT-2763 produced significantly less serum EPO compared with the vehicle group ( Figure 11B ).
Eleavated EPO levels in Hbb th3/+ mice upregulated Erfe, an erythroid regulatory hormone known to suppress hepcidin (17) . In agreement with reduced serum EPO, Erfe gene expression was significantly lower in spleens of Hbb th3/+ mice dosed with VIT-2763 compared with those treated with vehicle alone (Figure 11C ). Erfe is produced by erythrocyte precursors proliferating massively in spleens of Hbb th3/+ mice as a consequence of extramedullar erythropoiesis. Therefore, the effect of VIT-2763 on Erfe expression in spleen is mediated by reduced numbers of RBC precursors in the spleen.
Liver hepcidin (Hamp) expression in Hbb th3/+ and WT mice was similar and did not change upon VIT-2763 treatment ( Figure  11D) , as similarly reported for minihepcidin in Hbb th3/+ mice (18) . mitochondria ( Figure 9, A and B) . Strikingly, 10.3% (group average value) of mature RBCs from the Hbb th3/+ vehicle group preserved mitochondria and produced higher levels of ROS compared with RBCs without mitochondria (ratio of MFI of ROS pos MitoTracker pos to ROS pos MitoTracker neg RBCs = 2.5, group average value, representative dot plot shown in Figure 9A ). In Hbb th3/+ mice, VIT-2763 significantly reduced the proportion of mature RBCs containing mitochondria to an average of 4.9% ( Figure 9B ). Importantly, RBCs devoid of mitochondria produced lower levels of ROS (ROS pos MitoTracker neg populations in Figure 9A ). These data suggested that at least part of the oxidative stress in RBCs from Hbb th3/+ mice is mediated by erythrocytes that failed to eliminate their mitochondria. By improving erythropoiesis, VIT-2763 indirectly ameliorated mitophagy and decreased the oxidative stress in RBCs of Hbb th3/+ mice.
Increased ROS levels in RBCs of Hbb th3/+ mice cause membrane damage and lead to exposure of PS to the extracellular space. PS exposure to the outer cell membrane is an apoptotic signal and targets RBCs for phagocytosis (32) . VIT-2763 treatment of Hbb th3/+ mice significantly decreased PS exposure of RBCs and precursors of mature erythrocytes, as shown by annexin V staining ( Figure 10A and Supplemental Figure 4 ). PS exposure marks in correction of erythropoiesis, but also leads to amelioration of myelopoiesis in spleen. It remains to be investigated whether the quantitative changes in neutrophil populations also translate to functional improvement, i.e., chemotaxis, opsonization, and ROS production in response to bacterial challenge.
Discussion
The data in this paper summarize the discovery and preclinical efficacy of the oral ferroportin inhibitor VIT-2763. This small molecule drug has a mode of action similar to that of the peptide hepcidin: in cells, VIT-2763 blocked iron efflux with a potency similar to that of hepcidin, competed with hepcidin for ferroportin binding, and triggered ferroportin internalization and ubiquitination. Importantly, VIT-2763 improved the ineffective erythropoiesis, ameliorated anemia, and prevented liver iron loading in the Hbb th3/+ mouse model
Effects of VIT-2763 on myeloid precursors in spleens of Hbb th3/+ mice.
It has been previously shown that the proportion of immature myeloid cells is highly increased in spleens of Hbb th3/+ mice compared with WT, which suggested that the terminal neutrophil maturation in spleens of Hbb th3/+ mice is compromised (35) . Flow cytometry analysis of myelopoiesis in spleens confirmed a significant expansion of mature neutrophils ( Figure 12A , population i), immature myeloid cells (Figure 12 , population ii) and inflammatory monocytes ( Figure 12A , population iv) in Hbb th3/+ mice. VIT-2763 dosed for 3 weeks did not change the percentage of resident monocytes (population iii), however VIT-2763 significantly reduced the percentage of mature neutrophils (population i), immature myeloid cells (population ii) and inflammatory monocytes (population iv, Figure 12, A and B) . These data demonstrated that iron restriction by the ferroportin inhibitor VIT-2763 results not only Based on the mode of action described here, VIT-2763 is expected to correct ineffective erythropoiesis and iron overload in a range of diseases, such as hereditary hemochromatosis and hereditary anemias, e.g., thalassemia and sickle cell disease, or other hemoglobinopathies. In addition, VIT-2763 is expected to ameliorate myeloproliferative/myelodysplastic disorders, such as polycythemia vera and myelodysplastic syndrome (MDS). In a recently concluded phase I study in healthy individuals, VIT-2763 was well tolerated and showed a dose-linear PK profile. Importantly, serum iron was lowered and remained below baseline values up to 24 hours after the dose. Following these positive phase I results, Vifor Pharma intends to start a phase II proof-of-concept trial in β-thalassemia patients (22) .
All hepcidin-mimetics in clinical development, such as synthetic hepcidin, hepcidin peptidomimetics, or agents that of β-thalassemia. Presumably, VIT-2763 limits iron availability for formation of toxic α-globin aggregates and ROS in erythroid precursors and thereby improves erythropoiesis. As a result, more RBCs with extended life span ameliorate anemia and improve tissue oxygenation. VIT-2763 not only improved erythropoiesis, but also corrected the proportion of spleen myeloid precursors in Hbb th3/+ mice. VIT-2763 showed no cytotoxicity in assay detecting cellular ATP levels (IC 50 >100 μM). In nonclinical toxicology studies in rodents, the compound was well tolerated, with no observed adverse effect level (NOAEL) above 600 mg/kg in 14-day dosing studies with healthy rodents. In longer-term studies, there was no dose-limiting toxicity. The dose-limiting effects in healthy rodents were related to the pharmacology of VIT-2763 (restricting iron uptake) and the expected iron deficiency anemia and effects were secondary to that. ization activity in MDCK ferroportin internalization assay (data not shown), suggesting that the potency of compounds above a certain threshold in ferroportin-binding assay is necessary for detectable ferroportin internalization activity and confirming the appropriate choice of the screening strategy depicted in Figure 1A . VIT-2763 showed similar or higher potency in binding and iron efflux assays compared with hepcidin; however, the compound had about a 10-fold lower potency in the ferroportin internalization assay in MDCK cells. One possibility is that VIT-2763 directly blocks iron export by occluding ferroportin, which is similar to what has been shown for hepcidin (13) . The incomplete ferroportin degradation observed in MDCK cells even after 18 hours exposure to VIT-2763 might be suggestive of the occlusion mode of action. Cells expressing endocytosis-deficient ferroportin or RBCs, which lack endocytosis machinery, will be helpful to experimentally address the ability of VIT-2763 to occlude ferroportin. Interestingly, hepcidin triggered formation of detectable intracellular vesicles in MDCK cells, which were less pronounced in VIT-2763-treated cells. The different pattern of the intracellular vesicles in MDCK cells triggered by VIT-2763 might reflect distinct pathways of ferroportin degradation.
Immunoprecipitation studies in J774 cells showed that the small molecule VIT-2763 also triggered rapid ubiquitination of endogenous ferroportin, as previously shown for hepcidin (24) . It remains to be studied whether the different degree of ubiquitination of ferroportin induced by hepcidin and VIT-2763 targets ferroportin to different endocytic pathways. We have investigated the effect of VIT-2763 in duodenum, spleen, and liver by Western blot and quantitative PCR (qPCR) from Hbb th3/+ and WT mice. VIT-2763 did not reduce ferroportin levels in these tissues, as previously shown for minihepcidins (13) , despite substantially decreasing increase the production of endogenous hepcidin (siRNA or antisense DNA-targeting Tmprss6) are injectable drugs with higher molecular weight and no oral bioavailability. PK modeling using monkey plasma revealed that hepcidin has unfavorable pharmacological properties (t 1/2 <2.5 minutes) (36) and, because of its 4 disulfide bonds, is particularly difficult to synthesize. Activin receptor ligand traps, such as sotatercept and luspatercept, are clinical-stage biologics that modify late-stage erythrocyte precursor cell differentiation and maturation (37) . The longer halflife of these parenteral biologics offers the advantage of less frequent administration (once every 3 weeks) compared with an oral drug. However, the extended life span might become a disadvantage in cases of potential safety concerns. Indeed, the molecular target or targets of activin receptor traps are not well characterized, and reducing the activity of both known activin receptor ligands, GDF8 and GDF11, has been associated with increased risk of cardiovascular events (38) . Therefore, VIT-2763 is anticipated to be what we believe is the first oral ferroportin inhibitor in clinical development with a well-defined target profile and offering important advantages of small molecules over parenteral medicines.
Ferroportin inhibitors are a class of structurally related small molecules that have been identified and optimized based on their potency to inhibit binding and internalization of fluorescent hepcidin (TMR-hepcidin) in J774 cell-expressing endogenous ferroportin. In addition, the internalization assay using MDCK cells expressing human ferroportin revealed that VIT-2763 induced ferroportin internalization similarly to hepcidin, although with slower kinetics and smaller maximal response. Interestingly, the initial hits identified in the library by the TMR-hepcidin ferroportin binding assay in J774 cells essentially lacked ferroportin internal- One important consequence of iron restriction by VIT-2763 is the decreased formation of ROS in developing erythroblasts in BM and spleen as well as in RBCs of Hbb th3/+ mice. Interestingly, 10%-15% of mature RBCs in Hbb th3/+ mice have mitochondria, which are absent in WT RBCs. Similar abnormal retention of mitochondria in mature RBCs has been reported in patients and mice with sickle cell disease (41) . Moreover, RBCs with mitochondria produced excessive levels of ROS. In healthy individuals, mitochondria disappear from RBCs during development as an adaptation to avoid generation of ROS (42) . Notably, RBCs of Hbb th3/+ mice receiving VIT-2763 markedly reduced the proportion of mature RBCs containing mitochondria and producing elevated ROS, indicating improved terminal differentiation. To our knowledge, the effect of VIT-2763 on mitochondria in the Hbb th3/+ model has not been reported for other drugs targeting β-thalassemia.
VIT-2763 normalized myeloid spleen cell composition, most likely as a consequence of the corrected extramedullary erythropoiesis by VIT-2763. The ability of VIT-2763 to correct the proportion of spleen myeloid cells in the Hbb th3/+ model indicates a potential for decreasing inflammation in β-thalassemia. This effect has not been reported for other drugs targeting β-thalassemia.
Patients with non-transfusion-dependent β-thalassemia (NTDT) have a moderate anemia, but still develop iron overload due to ineffective erythropoiesis and inadequate hepcidin production. The most severe form of β-thalassemia, transfusion-dependent β-thalassemia (TDT), requires regular blood transfusions (more than 5 RBC transfusions in 24 weeks), leading to secondary iron overload requiring iron chelation therapy (43) . Blood transfusions and iron chelation therapy do not address the underlying pathological mechanism of the disease and are associated with increased risk of infection and adverse reactions.
The remarkable efficacy of VIT-2763 in Hbb th3/+ mice and the good tolerability profile in the nonclinical safety studies provide a direct rationale for investigating the efficacy of VIT-2763 in NTDT. VIT-2763 has not yet been tested in a mouse model of TDT. However, based on the mode of action of the compound, beneficial effects may be expected. Patients with TDT have severe iron overload due to regular blood transfusions. Blood transfusion causes a transient upregulation of hepcidin, which returns to basal values when the Hb levels decrease (44) . Prevention of intestinal iron absorption by VIT-2763 during the intervals between transfusions might help to reduce further iron loading in TDT patients. More importantly, blood transfusion generates nontransferrin bound iron (NTBI), which is released by macrophages recycling damaged RBCs and triggers oxidative stress and vascular damage (45) . Moreover, thalassemia patients on regular blood transfusions and chelation had elevated NTBI levels that correlated to the presence of heart disease (46) . The oral ferroportin inhibitor VIT-2763 might prevent these noxious effects by sequestrating iron in macrophages and therefore interrupting a vicious cycle in β-thalassemia. Scavenging NTBI by apo-transferrin treatment was found to attenuate transfusionmediated increases in plasma NTBI and associated excess tissue iron loading (47, 48) . Nevertheless, testing the efficacy of VIT-2763 in a TDT disease model will help to address this hypothesis.
In summary, by inhibiting ferroportin and thereby limiting the availability of iron to erythroid precursors, VIT-2763 decreases the formation of α-globin aggregates generating ROS and serum iron (data not shown). The absence of ferroportin degradation, together with the reduction of serum iron by VIT-2763, is consistent with the mechanism of ferroportin occlusion. The reasons for the differential effect of hepcidin agonists on ferroportin endocytosis in cells and tissues are not clear. One possibility, discussed by Aschemeyer et al. (13) , is different glycosylation of ferroportin and/or ferroportin-interacting proteins in cell lines versus tissues, which may differentially affect agonist binding to ferroportin and endocytosis pathways. Alternatively, the lack of degradation of ferroportin in spleen lysates could be due to analysis of the total membrane fraction (including plasma membrane and endosomes) by Western blot.
VIT-2763 is systemically available and most likely blocks iron export in all ferroportin-expressing tissues, including duodenum, spleen, and liver. Recent publications showed that ferroportin is highly abundant in mature RBCs and contributes a significant amount of iron to the blood (10, 11) . It is therefore plausible that erythroid ferroportin inhibition by VIT-2763 contributes to the fast reduction of systemic iron observed in rodents. We are currently addressing the effect of VIT-2763 on RBCs.
Our data showed VIT-2763 ameliorated anemia, improved erythropoiesis, and decreased organ iron loading in the Hbb th3/+ β-thalassemia intermedia disease model. Presumably, iron restriction by VIT-2763 slows down the formation of Hb in developing erythroid cells, leading to reduction of toxic α-globin aggregates in erythrocytes and associated oxidative stress. Similarly, induction of endogenous hepcidin by Tmprss6-targeting oligonucleotides or injection of hepcidin mimetics, such as minihepcidin in the Hbb th3/+ model resulted in decreased α-globin aggregates in membranes of RBCs (18) (19) (20) . Hb assembly is assisted by the molecular chaperone α-Hb-stabilizing protein (AHSP), which specifically binds to free α-globin chains before they associate with β-globin chains and prevents their aggregation (39) . However in β-thalassemia, excess α-globin chains exceed the capacity of AHSP and the unstable free α-globin molecules undergo autooxidation and generate ROS that initiates a cascade of events leading to hemolysis and ineffective erythropoiesis (40) . In addition, genetic evidence in patients supports the idea that reduction in α-globin chain, due to coinherited α-thalassemia, is beneficial in patients with β-thalassemia (3). The molecular mechanism of how iron restriction by ferroportin inhibition improves symptoms in β-thalassemia disease models needs further investigation.
VIT-2763 dose dependently decreased MCH, as shown previously for hepcidin and hepcidin agonists in the Hbb th3/+ model (20, 27) . These data indicate that iron restriction by VIT-2763 is reducing the erythroid iron intake per cell, resulting in lower MCH, but increasing the number of RBCs, thereby improving the anemia (total Hb is increased). Overall, the decrease in MCH and MCV is associated with beneficial effects in the thalassemia model. Therefore, dose-finding clinical studies with VIT-2763 will allow avoidance of excessive iron restriction and preserve a stable number of RBCs by tightly monitoring hematological indices, such as MCH, MCV, and RBC counts. The moderate half-life of VIT-2763 in plasma and the high degree of flexibility on dosing provide important advantages in finely tuning the dose for optimal iron-restriction effect. Ferritin-BLA reporter assay in HEK-FPN1-GFP cells. The HEK-FPN1-GFP ferritin-BLA cell clone was generated by stable integration of (a) a human FPN1-GFP fusion construct inserted into a derivative of the doxycycline-inducible pTRE-Tight-BI plasmid (Clontech) and (b) a human ferritin promoter-BLA reporter gene into a derivative of the HEK-293 Tet-ON Advanced cell line (Clontech). To generate the ferritin-BLA reporter gene construct, a 1.4 kb fragment of the human ferritin H promoter was amplified by PCR from human genomic DNA (forward primer, 5′-CAGGTTTGTGAGCATCCTGAA-3′; reverse primer, 5′-GGCGGCGACTAAGGAGAGG-3′) and inserted in front of the BLA gene present in the pcDNA 6.2/cGHFP-BLAzer-DEST plasmid (Thermo Fisher), thereby replacing the original CMV promoter and placing the iron response element (IRE) that regulates translation of the ferritin gene ca. 170 bp upstream of the start codon of the BLA reporter gene. HEK-BLA cells were seeded at 1.8 × 10 5 cells/ml in DMEM/F12 containing 10% FBS (Clontech), 1% penicillin-streptomycin, 200 μg/ml hygromycin B, 5 μg/ml, blasticidin (Thermo Fisher Scientific), and 4 μg/ml doxycycline (Clontech) in 384-well poly-dlysine-coated microplates. Dilution series of the test compound was added in quadruplicate, and plates were incubated overnight at 37°C. Cells were washed 3 times with HBSS. BLA activity was detected by adding the GeneBlazer reagent CCF4-AM (Thermo Fisher Scientific) to the cells. After incubation of the plates at 18°C for 60 minutes in darkness, blue and green fluorescence signals were measured in a Safire2 fluorescence plate reader (Tecan) with excitation at 410 nm and emissions at 458 nm (blue) and 522 nm (green). The ratio of blue (458 nm) and green (522 nm) fluorescence as a measure for BLA activity was calculated and EC 50 values were determined with the calculated blue/ green fluorescence ratios.
FPN1-HaloTag-TMR internalization assay in MDCK cells. The assay quantifies ferroportin internalization triggered by hepcidin or VIT-2763 through microscopic detection of the disappearance of cell surface-associated fluorescently labeled ferroportin in a MDCK cell clone. The MDCK cell clone stably expresses human ferroportin with a C-terminal HaloTag fusion (Promega) and could be covalently labeled with HaloTag TMR-ligand. Cells were plated at 3 × 10 5 cells/ ml in DMEM medium and grown at 37°C overnight. MDCK cells were stained with 2 μM HaloTag TMR-ligand (Promega) in growth medium for 20 minutes at 37°C, 5% CO 2 in the dark. Cells were then treated with serial dilutions of VIT-2763 or human hepcidin (Bachem) and incubated overnight at 37°C. Nuclei were counterstained with 3 μM Draq5 (eBioscience), and cells were washed twice with DPBS + CaCl 2 + MgCl 2 (BioTek 405 washer) and subsequently fixed with 4% paraformaldehyde in DPBS for 15 minutes. After 3 DPBS washes of cells, fluorescence images were acquired using an inverted IX81 epifluorescence microscope (ScanR, Olympus) and a ×20 high NA objective. Four pictures were acquired per well for each channel (TMR and CY5), and the acquired data were analyzed using the Columbus image data storage and analysis system (PerkinElmer). Texture analysis (SER-improves the efficiency of erythropoiesis. In turn, the resulting RBCs with increased Hb supply more oxygen to tissues, which suppresses the hypoxia response and normalizes iron absorption. The clinical development of the oral ferroportin inhibitor has the potential to provide a therapeutic option with dosing convenience for patients with β-thalassemia and other diseases with dysregulated iron homeostasis.
Methods
TMR-hepcidin internalization assay in J774 cells. J774 cells (DSMZ) harvested from 80% confluent cultures were plated at 8 × 10 5 cells/ ml in complete DMEM medium supplemented with FBS, penicillinstreptomycin (Gibco, Thermo Fisher Scientific), 200 μM Fe(III)-NTA (Fe[III}-chloride and Nitrilotriacetic acid, Sigma-Aldrich), in 96-well MicroClear plates (Greiner) and grown at 37°C. After overnight incubation, cells were washed and serial dilutions of test compounds were added in triplicate. J774 cells were preincubated with compounds for 15 minutes before addition of TMR-hepcidin (provided by Sukhi Bansal, King's College London, London, United Kingdom) at 25 nM. Cells were incubated for 2 hours, and Hoechst 33342 dye (Thermo Fisher Scientific) was added to a final concentration of 0.5 μg/ml. Cells were washed with Dulbecco's PBS (DPBS, Gibco, Thermo Fisher Scientific) and fixed using 5.3% paraformaldehyde (Electron Microscopy Sciences) for 15 minutes. TMR (530-550 nm excitation/575-625 nm emission/250 ms exposure time) and Hoechst 33342 fluorescence images were acquired using a ScanR Plate Imager (Olympus) with a ×20 high NA objective. Four pictures were acquired per well and fluorescence channel covering 1500 cells/well. The acquired data were analyzed with ScanR image analysis software. Image analysis included detection of nuclei, identification of cell-associated regions, application of a virtual channel, and thresholding for rolling-ball-type background reduction, followed by application of the sum(mean) algorithm to measure the TMR fluorescence associated with cells as a quantitative measure for internalized TMR-hepcidin.
Fluorescence polarization assay with recombinant human ferroportin and TMR-hepcidin. A mixture of 1.95 μM human recombinant ferroportin isolated from Pichia pastoris yeast cells expressing human ferroportin with a C-terminal FLAG affinity tag (49) and 30 nM TMRhepcidin in FP assay buffer containing 50 mM Tris-HCl pH 7.3, 200 mM NaCl (Sigma-Aldrich), 0.02% n-dodecyl-β-d-maltopyranoside (DDM) (D310S, Sol-Grade 98% pure, Anatrace), 0.1% BSA (Sigma Aldrich), was plated into a 384-well black low-volume round-bottom plate (Corning) at 16 μl per well. A volume of 8 μl of serial dilutions of test compounds were added in duplicates to reach final ferroportin and TMR-hepcidin concentrations of 0.65 μM and 10 nM, respectively. Plates were incubated for 90 minutes at room temperature and parallel (Fpara) and perpendicular (Fperp) fluorescence was measured in a Synergy H1 fluorescence reader (BioTek). FP values were calculated in mP according to the following formula: mP = ((Fpara -Fperp)/(Fpara + Fperp)) × 1000.
Iron efflux assay in T47D cells. Human T47D (ECACC) epithelial breast cancer cells were plated in 24-well plates (Greiner) at 350,000 cells/well and incubated overnight with 100 μM 58 Fe(II) sulfate (Vifor [International] Ltd.) in 500 μM l-ascorbic acid (Sigma Aldrich) containing DMEM growth medium. T47D cells were washed once with 500 μl iron uptake buffer (IUB) (20 mM PIPES, 5 mM glucose monohydrate, 130 mM NaCl, 10 mM KCl, 1 mM MgSO 4 ), then once with jci.org Volume 130 Number 1 January 2020
RBCs were detected with the indicator CM-H2DCFDA (Invitrogen) after gating on Ter119 + and CD71cells. Myelopoiesis was assessed in single spleen cell suspension. Mature neutrophils were identified as CD11b + Ly6G hi Ly6C int , immature myeloid cells were identified as CD11b + Ly6G int Ly6C int , inflammatory monocytes were identified as CD11b + Ly6G neg Ly6C hi , and resident monocytes were identified as CD11b + Ly6G neg Ly6C int using FITC-conjugated rat anti-mouse CD11b (catalog 11-0112-82), PE-conjugated rat anti-mouse Ly6G (catalog 12-9668-82), and APC-conjugated rat anti-mouse Ly6C (catalog 17-5932-82) all from eBioscience. Mitochondria were detected using MitoTracker Deep Red FM (Invitrogen) in RBCs labeled with Ter119 and CD71 antibodies in a combination with CM-H2DCFDA staining for ROS detection. Intracellular hypoxia was measured using the ROS-ID Hypoxia/ Oxidative Stress Detection Kit (Enzo Life Sciences, ENZ-51042-K500). RBCs were labeled with Ter119 antibody and incubated with the hypoxia detection probe according to the manufacturer's instructions. PS exposure was detected using the Annexin V Apoptosis Detection Kit (Invitrogen) on peripheral blood cells labeled with Ter119 and CD71 antibodies.
Statistics. For quantification of EC 50 or IC 50 in the assays, for each data set, the fit of the log(inhibitor) vs. response (3 parameters) model was compared with the fit of the log(inhibitor) vs. response -variable slope (4 parameters) model and the data of the preferred model were used. Statistical analysis for parameters over time course was performed using a 2-way ANOVA with repeated measures for time-course effects. Where significant effects were observed, post tests were performed using Dunnett's multiple comparison test. For analysis of endpoint parameters, 1-way ANOVA with Dunnett's multiple comparison test was used. Data are presented by individual value with mean as scatter plots. Significant differences between treatment groups compared with Hbb th3/+ vehicle group are indicated. Statistical analyses and EC 50 /IC 50 value calculations were carried out with Prism software (GraphPad Prism version 7.04).
See Supplemental Methods for additional information. Study approval. The animal studies described in this paper complied with all applicable sections of the law and associated guidelines and were approved by the Veterinary Department of Zurich. All studies were also performed in compliance with the Code of Conduct of Vifor Pharma Group.
